Production is scheduled to start in December and to begin export deliveries of vaccine in January 2021.
According to TASS, the Russian Direct Investment Fund (RDIF) and South Korean company GL Rapha have reached an agreement to produce over 150 million doses of Sputnik V coronavirus vaccine annually in South Korea.
“Russian Direct Investment Fund and GL Rapha, one of South Korea’s leading biotechnology companies (including a subsidiary of Hankook Korus Pharm), announce an agreement to produce more than 150 million doses of Sputnik V, the world’s first registered coronavirus vaccine, in the country”, – a statement published in an official vaccine Twitter account.
The first interim analysis of data from the third phase of clinical trials in Russia demonstrated 92% efficiency of Sputnik V vaccine application.
It is noted that the parties intend to start production in December and start export deliveries of the vaccine in January 2021. The vaccine produced will enter the world market.